

# CITATION REPORT

List of articles citing

## Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

DOI: [10.1056/nejmoa1803675](https://doi.org/10.1056/nejmoa1803675)

New England Journal of Medicine, 2018, 379, 417-427.

**Source:** <https://exaly.com/paper-pdf/71697981/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
576	Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery. <b>2018</b> , JCO1801198		
575	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. <b>2019</b> , 13, 166-174		7
574	Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era. <b>2018</b> , 52, 419-426		10
573	Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift?. <b>2018</b> , 105 Suppl 3, S229-S234		1
572	[French ccAFU guidelines' Update 2018-2020: Management of kidney cancer]. <b>2018</b> , 28 Suppl 1, R5-R33		1
571	[Cytoreduction nephrectomy: No future?]. <b>2018</b> , 105, 981-984		0
570	Sunitinib Alone or after Nephrectomy in Renal Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1878-1887	59.2	3
569	Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment. <b>2018</b> , 19,		17
568	Adjuvant sunitinib in patients with high-risk renal cell carcinoma: A closer look. <b>2018</b> ,		
567	Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience. <b>2018</b> , 16, e1189-e1199		2
566	[Management of metastatic renal cell carcinoma]. <b>2018</b> , 28, 777-782		0
565	Nephrektomie bei Nierenkrebsmetastasen obsolet?. <b>2018</b> , 21, 16-17		
564	RETRACTED: Recommandations françaises du Comité de Cancérologie de l'AFU Actualisation 2018-2020: prise en charge du cancer du rein French ccAFU guidelines Update 2018-2020: Management of kidney cancer. <b>2018</b> , 28, S3-S31		8
563	Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. <b>2018</b> , 13, 705-714		24
562	Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. <b>2018</b> , 392, 2353-2366		510
561	Renal cell carcinoma: standards and controversies. <b>2018</b> , 36, 1889-1890		11
560	Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era. <b>2018</b> , 36, 499.e1-499.e7		4

559	ASCO vom amerikanischen Krebskongress 2018. <b>2018</b> , 24, 731-734	
558	Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. <b>2018</b> , 56, 118-125	9
557	Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study. <b>2018</b> , 16, e1221-e1235	8
556	Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. <b>2018</b> , 74, 805-809	47
555	Cytoreductive nephrectomy in metastatic renal cancer - less is more. <b>2018</b> , 15, 595-596	3
554	The role of nephrectomy in metastatic renal cell carcinoma. <b>2018</b> , 14, 601-602	2
553	Has the Age of Cytoreductive Nephrectomy Come to an End?: Commentary on: Sunitinib Alone or After Nephrectomy in Metastatic Renal-Cell Carcinoma. <b>2018</b> , 121, 1-2	1
552	Cytoreductive nephrectomy: questions remain after CARMENA. <b>2018</b> , 15, 530-532	5
551	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <b>2018</b> , 36, 1973-1980	5
550	Perspectives on Geriatric Oncology Research presented at the 2018 American Society of Clinical Oncology Annual Meeting. <b>2018</b> , 9, 419-422	1
549	A systematic review and meta-analysis of clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with tumor thrombus treated by radical nephrectomy with thrombectomy. <b>2018</b> , 69, 112-120	13
548	Cytoreductive Nephrectomy - Patient Selection Is Key. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 481-482	61
547	Ist die zytoreduktive Nephrektomie beim mRCC noch Standard?. <b>2019</b> , 22, 16-17	
546	Nephrektomie weiterhin Standard?. <b>2019</b> , 22, 24-25	
545	Lokale Radiotherapie beim mPC?. <b>2019</b> , 22, 32-34	
544	When Should we Irradiate the Primary in Metastatic Lung Cancer?. <b>2019</b> , 31, 815-823	1
543	Stereotactic Body Radiation Therapy for Renal Cell Carcinoma with Inferior Vena Cava Thrombus - Initial Experience Report and Literature Review. <b>2019</b> , 3, 71-77	2
542	Overexpression of miR-15b Promotes Resistance to Sunitinib in Renal Cell Carcinoma. <b>2019</b> , 10, 3389-3396	17

541	Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. <b>2019</b> , 5, 927-929	8
540	Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database. <b>2020</b> , 14, 24-30	2
539	Trends in Palliative Surgical Care. <b>2019</b> , 53, 69-81	1
538	Efficacy of cryoablation for paroxysmal and persistent atrial fibrillation in patients with structural heart disease. <b>2019</b> , 74, 543	1
537	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). <b>2019</b> , 105, 3-12	7
536	Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. <i>Eur Urol</i> 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End. <b>2019</b> , 2, 403-404	1
535	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. <b>2019</b> , 13, 343-354	8
534	Response of Primary Renal Cell Carcinoma to Systemic Therapy. <b>2019</b> , 76, 852-860	4
533	Recent advances and application of PD-1 blockade in sarcoma. <b>2019</b> , 12, 6887-6896	11
532	First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options. <b>2019</b> , 14, 639-645	9
531	Complications associated with perioperative use of tyrosine kinase inhibitor in cytoreductive nephrectomy. <b>2019</b> , 9, 15272	1
530	Presurgical Pazopanib Improves Surgical Outcomes for Renal Cell Carcinoma With High-level IVC Tumor Thrombosis. <b>2019</b> , 33, 2013-2019	4
529	Cytoreductive nephrectomy in the current treatment algorithm. <b>2019</b> , 11, 1758835919879026	8
528	Patient characteristics and treatments one year after diagnosis of renal cancer in 2015 according to the presence or absence of metastasis and a history of another tumour: A national observational study. <b>2019</b> , 106, 538-549	0
527	The Changing Therapeutic Landscape of Metastatic Renal Cancer. <b>2019</b> , 11,	25
526	[50 years of renal cell carcinoma]. <b>2019</b> , 50, 378-385	1
525	Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma. <b>2019</b> , 51, 2181-2188	6
524	Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios. <b>2019</b> , 51, 2107-2117	2

523	Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. <b>2019</b> , 37, 2961-2967	10
522	Radiotherapy for metastatic prostate cancer. <b>2019</b> , 394, 829-830	0
521	[Treatment of primary disease (breast, non-small cell lung and prostate cancers) with irradiation in case of de novo metastatic cancer]. <b>2019</b> , 23, 486-495	2
520	Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. <b>2019</b> , 37, 811.e9-811.e16	4
519	[Cytoreductive nephrectomy for metastatic renal cell carcinoma - obsolete?]. <b>2019</b> , 58, 51-52	1
518	Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database. <b>2019</b> , 37, 294.e1-294.e8	2
517	Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma. <b>2019</b> , 19, 259-271	3
516	Evolving Clinical Picture of Renal Cell Carcinoma: A Population-Based Study from Helsinki. <b>2019</b> , 102, 390-398	1
515	New entities, new technologies, new findings: A review of the cytologic features of recently established subtypes of renal cell carcinoma. <b>2019</b> , 127, 79-97	8
514	Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud M[Jean], Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842-3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoin	2
513	The current treatment patterns of metastatic renal cell carcinoma: A national cancer database review, 2004-2015. <b>2019</b> , 12, 266-273	0
512	[Some important breakthroughs in oncology and hematology in 2018: A selection by the editorial board of Bulletin du Cancer]. <b>2019</b> , 106, 12-23	0
511	Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. <b>2019</b> , 17, e447-e453	12
510	Percutaneous renal mass biopsy: historical perspective, current status, and future considerations. <b>2019</b> , 19, 301-308	8
509	Cytoreductive nephrectomy is dead, long live cytoreductive nephrectomy. <b>2019</b> , 124, 6-7	2
508	Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives. <b>2019</b> , 12, 137-141	
507	Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME). <b>2019</b> , 76, 437-440	16
506	Personalized approach to systemic therapy of renal cancer. <b>2019</b> , 4, 179-188	

505	The CANLPH Score, an Integrative Model of Systemic Inflammation and Nutrition Status (SINS), Predicts Clinical Outcomes After Surgery in Renal Cell Carcinoma: Data From a Multicenter Cohort in Japan. <b>2019</b> , 26, 2994-3004	7
504	Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma. <b>2019</b> , 37, 727-734	6
503	Does CARMENA mark the end of cytoreductive nephrectomy for metastatic renal cell carcinoma?. <b>2019</b> , 37, 525-528	
502	Perioperative and oncologic outcome in patients treated for renal cell carcinoma with an extended inferior vena cava tumour thrombus level II-IV. <b>2019</b> ,	2
501	Shared Decision-Making for Patients with Advanced Urological Malignancies: Evaluation of a Joint Urological-Oncological Clinic Model. <b>2019</b> , 42, 366-374	4
500	A Retrospective Analysis of the Impact of Metastasectomy on Prognostic Survival According to Metastatic Organs in Patients With Metastatic Renal Cell Carcinoma. <b>2019</b> , 9, 413	9
499	Many Elderly Patients With Stage IV Metastatic Renal Cell Carcinoma May Benefit From More-Aggressive Treatment. <b>2019</b> , 2, e195815	2
498	Multiple angiomyolipomas mimicking metastases of concurrent clear cell renal cell carcinoma. <b>2019</b> , 2, 162-165	
497	Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry. <b>2019</b> , 8, 3401-3410	6
496	A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. <b>2019</b> , 120, 1113-1119	42
495	Reassessing the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in 2019. <b>2019</b> , 39, 276-283	6
494	Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?. <b>2019</b> , 6, 1-7	8
493	Early Changes in CT Perfusion Parameters: Primary Renal Carcinoma Versus Metastases After Treatment with Targeted Therapy. <b>2019</b> , 11,	4
492	Adding Nanotechnology to the Metastasis Treatment Arsenal. <b>2019</b> , 40, 403-418	15
491	The use of cytoreductive nephrectomy in patients with renal cell carcinoma. <b>2019</b> , 19, 405-411	1
490	Possible Drop Metastasis After Treatment of Renal Cell Carcinoma With Percutaneous Cryoablation. <b>2019</b> , 130, 17-19	1
489	The value of cytoreductive nephrectomy on the survival of metastatic renal carcinoma patients based on the number of site-specific metastases. <b>2019</b> , 14, e0215861	5
488	Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys". <b>2019</b> , 20,	27

487	Metastasectomy in Advanced Renal Cell Carcinoma: A Systematic Review. <b>2019</b> , 3, 31-40	1
486	Towards individualized therapy for metastatic renal cell carcinoma. <b>2019</b> , 16, 621-633	83
485	Metastatic Renal Cell Carcinoma with Level IV Thrombus: Contemporary Management with Complete Response to Neoadjuvant Targeted Therapy. <b>2019</b> , 2019, 7102504	6
484	Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma. <b>2019</b> , 21, 34	20
483	[Local radiotherapy for patients with newly diagnosed, metastatic prostate cancer]. <b>2019</b> , 195, 362-364	
482	Re: Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. <b>2019</b> , 75, 876-877	1
481	Disagreement in risk groups for metastatic renal cancer. <b>2019</b> , 16, 332-333	2
480	US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology: A Dangerous Precedent?. <b>2019</b> , 5, 607-608	6
479	Patterns of Presentation and Treatment Outcomes of Non-clear-cell Renal Cell Carcinoma and Sarcomatoid Renal Cell Carcinoma Patients in 2 Tertiary Referral Centers in Sydney, Australia. <b>2019</b> , 17, e565-e569	1
478	Upfront cytoreductive nephrectomy vs. upfront systemic therapy in metastatic kidney cancer. <b>2019</b> , E377-E381	2
477	Current status of prognostic factors in patients with metastatic renal cell carcinoma. <b>2019</b> , 26, 608-617	15
476	Metastasiertes Nierenzellkarzinom: Nephrektomie plus Sunitinib versus Sunitinib. <b>2019</b> , 50, 132-136	
475	Surgery for high-risk locally advanced (pT3c) renal tumours: oncological outcomes and prognostic significance of a modified International Metastatic Renal Cell Cancer Database Consortium (IMDC) score. <b>2019</b> , 124, 462-468	2
474	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. <b>2019</b> , 37, 529.e1-529.e7	4
473	Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival. <b>2019</b> , 37, 577.e9-577.e16	3
472	Cryoablation for paroxysmal and persistent AF in patients with structural heart disease and preserved ejection fraction: Clinical outcomes from 1STOP, a multicenter observational project. <b>2019</b> , 74, 19-26	8
471	Overview of current and future systemic therapy for metastatic renal cell carcinoma. <b>2019</b> , 49, 395-403	21
470	Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up <b>2019</b> , 30, 706-720	372

469	Cytoreductive prostatectomy: what is the evidence? A systematic review. <b>2019</b> , 71, 1-8	6
468	The Emerging Role of Combination Angiogenesis Inhibitors and Immune Checkpoint Inhibitors in the Treatment of Metastatic Renal Cell Cancer. <b>2019</b> , 3, 81-91	1
467	[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. <b>2019</b> ,	1
466	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <b>2019</b> , 2, 643-648	19
465	Re: Arnaud M Jean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?. <b>2019</b> , 2, 340-341	3
464	Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?. <b>2019</b> , 2, 365-378	30
463	Cytoreductive Nephrectomy in the Wake of CARMENA: When to Consider it. <b>2019</b> , 2, 379-380	3
462	[Specificity of the management of metastatic renal cancer in the older patient]. <b>2019</b> , 29, 874-895	1
461	Cytoreductive nephrectomy in metastatic kidney cancer: what do we do now?. <b>2019</b> , 13, 255-261	2
460	TGF- $\beta$ and microRNA Interplay in Genitourinary Cancers. <b>2019</b> , 8,	9
459	Contemporary Renal Tumor Categorization With Biomarker and Translational Updates: A Practical Review. <b>2019</b> , 143, 1477-1491	8
458	Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options. <b>2019</b> , 15 Suppl 10, 3-10	3
457	Is cytoreductive nephrectomy relevant in the immunotherapy era?. <b>2019</b> , 29, 526-530	4
456	The evolving role of cytoreductive nephrectomy: incorporating genomics of metastatic renal cell carcinoma into treatment decisions. <b>2019</b> , 29, 531-539	1
455	Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology. <b>2019</b> , 29, 521-525	3
454	Treating the primary in metastatic prostate cancer: where do we stand?. <b>2019</b> , 13, 243-248	3
453	Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors. <b>2019</b> , 29, 513-520	4
452	The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma. <b>2019</b> , 29, 507-512	5



451	Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. <b>2019</b> , 2, 355-364	15
450	Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma. <b>2019</b> , 37, 78-85	11
449	Cytoreductive Nephrectomy: Assessing the Generalizability of the CARMENA Trial to Real-world National Cancer Data Base Cases. <b>2019</b> , 75, 352-353	22
448	Treatment of the primary tumor in metastatic prostate cancer. <b>2019</b> , 37, 2597-2606	7
447	Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. <b>2019</b> , 75, 111-128	82
446	Radical shifts in the first-line management of metastatic renal cell carcinoma. <b>2019</b> , 16, 71-72	2
445	Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres. <b>2019</b> , 58, 306-312	2
444	Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer: Not All That It's Cut Out to Be. <b>2019</b> , 5, 171-172	8
443	Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. <b>2019</b> , 5, 164-170	180
442	Preoperative apolipoprotein B/A1 ratio is an independent prognostic factor in metastatic renal cell carcinoma. <b>2019</b> , 37, 184.e9-184.e17	9
441	Sunitinib and Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. <b>2019</b> , 201, 453-454	2
440	Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma - A retrospective study. <b>2020</b> , 26, 556-563	2
439	Overview on the role of preoperative therapy in the management of kidney cancer. <b>2020</b> , 22, 11-20	2
438	The role and timing of cytoreductive nephrectomy in the immunotherapy era. <b>2020</b> , 6, 7-8	0
437	Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: How to Apply New Evidence in Clinical Practice. <b>2020</b> , 98, 1-9	10
436	Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. <b>2020</b> , 3, 94-101	17
435	Utilization of Stereotactic Ablative Body Radiation Therapy for Intact Renal Cell Carcinoma: Trends in Treatment and Predictors of Outcome. <b>2020</b> , 5, 85-91	2
434	Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients. <b>2020</b> , 11, 718-723	11

433	The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience. <b>2020</b> , 136, 169-175	6
432	A review of checkpoint inhibitors in the management of renal cell carcinoma. <b>2020</b> , 26, 445-458	5
431	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. <b>2020</b> , 4, 29-39	1
430	Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values. <b>2020</b> , 23, 100166	14
429	Urology highlights 2017 to 2018. <b>2020</b> , 13, 178-184	
428	Can I Get a Multidisciplinary Consult, Please? Systemic Immunotherapy and the Timing of Cytoreductive Nephrectomy. <b>2020</b> , 6, 9-10	0
427	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. <b>2020</b> , 3, 47-56	12
426	A 22-year experience with pancreatic resection for metastatic renal cell carcinoma. <b>2020</b> , 22, 312-317	6
425	Neoadjuvant checkpoint inhibition in renal cell carcinoma associated Stauffer's syndrome. <b>2020</b> , 29, 101077	2
424	Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?. <b>2020</b> , 77, 761-763	18
423	Inferior vena cava thrombectomy following complete response to nivolumab/ipilimumab for metastatic renal cell carcinoma. <b>2020</b> , 90, 1517-1519	4
422	Radical cytoreductive prostatectomy in men with prostate cancer and oligometastatic disease. <b>2020</b> , 30, 90-97	3
421	Cytoreductive nephrectomy: does CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) change everything?. <b>2020</b> , 30, 36-40	2
420	Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. <b>2020</b> , 49, 55-62	25
419	Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? No, cytoreductive nephrectomy should no longer be routinely performed. <b>2020</b> , 30, 743-745	1
418	Cytoreductive Nephrectomy in Patients Presenting With Advanced Disease: Have We Finally Answered the Question?. <b>2020</b> , 26, 382-389	1
417	PBA2, a novel compound, enhances radiosensitivity in various carcinoma cells by activating the p53 pathway in vitro and in vivo. <b>2020</b> , 161, 224-233	0
416	Kidney Cancer: An Overview of Current Therapeutic Approaches. <b>2020</b> , 47, 419-431	37

415	Global change of surgical and oncological clinical practice in urology during early COVID-19 pandemic. <b>2021</b> , 39, 3139-3145	6
414	Re: Urological surgery in the COVID-19 era: Patient counselling and informed consent. <b>2020</b> , 18, 134	1
413	Advances in urologic oncology OncoForum™The best of 2019. <b>2020</b> , 44, 586-596	0
412	Advances in urologic oncology "OncoForum": The best of 2019. <b>2020</b> , 44, 586-596	
411	Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be considered. <b>2020</b> , 30, 740-742	1
410	Cytoreductive nephrectomy in primary metastatic clear cell renal cell carcinoma. <b>2020</b> , 54, 500	
409	The role of surgery on the primary tumor site in bladder cancer with distant metastasis: significance of histology type and metastatic pattern. <b>2020</b> , 9, 9293-9302	3
408	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. <b>2020</b> , 98, 1108-1119	10
407	Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry. <b>2020</b> , 12,	5
406	Contemporary trends in percutaneous renal mass biopsy utilization in the United States. <b>2020</b> , 38, 835-843	6
405	Pediatric and young adult renal cell carcinoma. <b>2020</b> , 67, e28675	2
404	The clinical significance of routine risk categorization in metastatic renal cell carcinoma and its impact on treatment decision-making: a systematic review. <b>2020</b> , 16, 2879-2896	0
403	Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date. <b>2020</b> , 12, 7321-7330	10
402	Metastatic renal cell carcinoma patients of T4 stage who are in status of N1 stage or older than 76 years cannot benefit from cytoreductive nephrectomy. <b>2020</b> , 20, 844	2
401	Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma. <b>2020</b> , 54, 493-499	2
400	Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting. <b>2020</b> , 54, 487-492	0
399	Nomogram Predicting Survival to Assist Decision-Making of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma. <b>2020</b> , 10, 592243	2
398	Cytoreductive nephrectomy in metastatic renal cell carcinoma. <b>2020</b> ,	

397	Therapie des oligometastasierten Prostatakarzinoms. <b>2020</b> , 23, 45-55	
396	Pushing the limits of metastasis-directed treatment in metastatic renal cell carcinoma in the era of targeted therapy. <b>2020</b> , 38, 937.e1-937.e9	1
395	Development and validation of a nomogram to predict overall survival for patients with metastatic renal cell carcinoma. <b>2020</b> , 20, 1066	7
394	Nephrectomy Status in the Context of Cabozantinib Treatment. <b>2020</b> , 4, 1-2	
393	Onko-Nephrologie. <b>2020</b> ,	
392	Establishment of predictive model for patients with kidney cancer bone metastasis: a study based on SEER database. <b>2020</b> , 9, 523-543	4
391	Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices. <b>2020</b> , 9,	3
390	Complex surgery and perioperative systemic therapy for genitourinary cancer of the retroperitoneum. <b>2020</b> , 27, e34-e42	
389	The construction and analysis of competitive endogenous RNA (ceRNA) networks in metastatic renal cell carcinoma: a study based on The Cancer Genome Atlas. <b>2020</b> , 9, 303-311	4
388	Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma. <b>2020</b> , 18, 361-366	4
387	Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma. <b>2020</b> , 18, e730-e738	4
386	Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma. <b>2020</b> , 3, 523-529	13
385	Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. <b>2020</b> , 20, 491-501	6
384	Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG). <b>2020</b> , 146, 1829-1845	1
383	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. <b>2020</b> , 78, 29-42	71
382	Safety of sunitinib in patients with renal cell carcinoma following nephrectomy. <b>2020</b> , 19, 799-806	0
381	Genitourinary cancer management during a severe pandemic: Utility of rapid communication tools and evidence-based guidelines. <b>2020</b> , 1, 45-59	3
380	The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma. <b>2020</b> , 24, 100183	5

379	Stereotactic Ablative Radiotherapy for T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK). <b>2020</b> , 108, 941-949	15
378	Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors. <b>2020</b> , 47, 359-370	5
377	Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines. <b>2020</b> , 78, 321-326	9
376	[What is new in the diagnosis and therapy of renal cell carcinoma?]. <b>2020</b> , 145, 734-739	2
375	Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab. <b>2020</b> , 13, 4021-4034	3
374	Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. <a href="https://doi.org/10.1016/j.eururo.2019.12.018">https://doi.org/10.1016/j.eururo.2019.12.018</a> : The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition. <b>2020</b> , 78, e78-e80	1
373	Management of Metastatic Renal Cell Carcinoma with Variant Histologies. <b>2020</b> , 47, 319-327	1
372	Minimally Invasive Surgery for Patients with Locally Advanced and/or Metastatic Renal Cell Carcinoma. <b>2020</b> , 47, 389-397	4
371	Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma. <b>2020</b> , 47, 329-343	4
370	Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. <a href="https://doi.org/10.1016/j.eururo.2020.04.038">https://doi.org/10.1016/j.eururo.2020.04.038</a> : Cytoreductive Nephrectomy: To Whom and When?. <b>2020</b> , 3, 559-560	1
369	Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. <b>2020</b> , 126, 3950-3960	14
368	Personalizing preoperative risk stratification and refining patient selection for cytoreductive nephrectomy in metastatic renal cell carcinoma. <b>2020</b> , 126, 3912-3915	2
367	Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review. <b>2020</b> , 18, e688-e691	6
366	Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma. <b>2020</b> , 22, 35	1
365	Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. <b>2020</b> , 17, 271-291	13
364	Renal cell carcinoma revealed by sternal tumefaction: A rare case report and literature review. <b>2020</b> , 31, 101137	0
363	Stereotactic Body Radiotherapy for Stage I Renal Cell Carcinoma: National Treatment Trends and Outcomes Compared to Partial Nephrectomy and Thermal Ablation. <b>2020</b> , 31, 564-571	4
362	Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era. <b>2020</b> , 38, 515-520	8

361	New prognostic model for synchronous metastatic renal cell carcinoma. <b>2020</b> , 27, 448-456	2
360	Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach. <b>2020</b> , 38, 3199-3205	3
359	The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinoma. <b>2020</b> , 23, 100169	5
358	Choice of Surgical Options in Kidney Cancer and Surgical Complications. <b>2020</b> , 40, 42-48	4
357	Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population. <b>2020</b> , 6, 19-26	0
356	The immunotherapy revolution in genitourinary malignancies. <b>2020</b> , 12, 819-831	7
355	The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort. <b>2020</b> , 38, 739.e9-739.e15	7
354	Evolving Role of Urologists in the Management of Advanced Renal Cell Carcinoma. <b>2020</b> , 47, 271-280	2
353	An evaluation of the role of tumor load in cytoreductive nephrectomy. <b>2020</b> , 14, E625-E630	0
352	Evidence of survival benefit was often ambiguous in randomized trials of cancer treatments. <b>2020</b> , 127, 1-8	
351	Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. <b>2020</b> , 126, 745-753	9
350	Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression. <b>2020</b> , 21,	9
349	Characteristics, dynamic changes, and prognostic significance of TCR repertoire profiling in patients with renal cell carcinoma. <b>2020</b> , 251, 26-37	7
348	Treatment of Primary in Metastatic Prostate Cancer: What Is the Standard of Care?. <b>2020</b> , 26, 83-86	
347	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <b>2020</b> , 3, 530-539	14
346	Results of the ADAPT Phase 3 Study of Rocabudencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. <b>2020</b> , 26, 2327-2336	21
345	Current State of Systemic Therapies for Advanced Renal Cell Carcinoma. <b>2020</b> , 22, 26	18
344	SEOM clinical guideline for treatment of kidney cancer (2019). <b>2020</b> , 22, 256-269	8

343	Deferred Cyto-reductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data. <b>2020</b> , 3, 168-173	9
342	Perioperative Outcome of Suprarenal Resection of Vena Cava Without Reconstruction in Urologic Malignancies: A Case Series and Review of the Literature. <b>2020</b> , 142, 146-154	5
341	Deferred Cyto-reductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. <b>2020</b> , 78, 615-623	19
340	The Effect of Cyto-reductive Partial Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma. <b>2020</b> , 15, 431-439	2
339	[Recommendations CCAFU on the management of cancers of the urogenital system during an epidemic with Coronavirus COVID-19]. <b>2020</b> , 30, 221-231	20
338	Improved survival after cyto-reductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. <b>2020</b> , 38, 604.e9-604.e17	25
337	Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors. <b>2020</b> , 43, 58-63	11
336	(, ) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. <b>2020</b> , 8,	28
335	Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma. <b>2020</b> , 40, 1-10	10
334	Primum Non Nocere: When Nephrectomy Becomes a Selective Approach in Metastatic Renal Cell Carcinoma. <b>2020</b> , 3, 174-175	0
333	Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. <b>2020</b> , 20, 343-354	
332	Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cyto-reductive surgery. <b>2020</b> , 32, 240-249	8
331	Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis. <b>2021</b> , 39, 461-472	8
330	RETRACTED ARTICLE: Comprehensive characterization of tumor mutation burden in clear cell renal cell carcinoma based on the three independent cohorts. <b>2021</b> , 147, 1745	4
329	Management of urologic cancers during the pandemic and potential impact of treatment deferrals on outcomes. <b>2021</b> , 39, 258-267	4
328	Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cyto-reductive nephrectomy. <b>2021</b> , 51, 296-304	4
327	Surgical resection of the primary lesion for osteosarcoma patients with metastasis at initial diagnosis. <b>2021</b> , 51, 416-423	1
326	Preventive strategies for acute kidney injury in cancer patients. <b>2021</b> , 14, 70-83	9

325	A Contemporary Analysis of the 30-day Morbidity and Mortality Associated With Cytoreductive Nephrectomy. <b>2021</b> , 147, 186-191	2
324	The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma. <b>2021</b> , 21, 401-412	4
323	Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study. <b>2021</b> , 28, 369-375	5
322	Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. <b>2021</b> , 39, 77.e17-77.e25	9
321	Clinical outcomes of radical surgery in patients with renal carcinoma and associated venous thrombosis: Single-centre experience in a tertiary care institution. <b>2021</b> , 75, e13811	0
320	Immediate preoperative renal artery embolization in the resection of complex renal tumors (UroCCR-48 Reinbol study). <b>2021</b> , 53, 229-234	1
319	Metastatic renal cell carcinoma presenting as jaundice with biliary and gastric outlet obstruction. A case report. <b>2021</b> , 2021, rjaa591	1
318	Urology. <b>2021</b> , 407-423	
317	Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma. <b>2021</b> , 22, 15	3
316	Cytoreductive stereotactic body radiotherapy (SBRT) and combination SBRT with immune checkpoint inhibitors in metastatic renal cell carcinoma. <b>2021</b> , 15, 281-286	1
315	Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database. <b>2021</b> , 20, 15330338211019507	0
314	Experience with management of renal cell carcinoma with inferior vena cava/right atrial tumor thrombus. <b>2021</b> , 37, 234-240	1
313	Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis. <b>2021</b> , 13,	2
312	Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma. <b>2021</b> , 11, e328	6
311	Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?. <b>2020</b> , 10, 627025	0
310	Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma. <b>2021</b> , 11, 607595	1
309	Systemtherapie beim metastasierten Nierenzellkarzinom. <b>2021</b> , 23, 25-27	
308	Câncer renal. <b>2021</b> , 13, 1431-1440	



307	Metastases to the Kidney: An Analysis of 35 Cases and a Review of Literature. <b>2020</b> , 10, 632221	1
306	Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era. <b>2021</b> , 41, 1-11	2
305	Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy. <b>2021</b> , 31, 262-269	6
304	Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review. <b>2021</b> ,	5
303	Identification of a Risk Stratification Model to Predict Overall Survival and Surgical Benefit in Clear Cell Renal Cell Carcinoma With Distant Metastasis. <b>2021</b> , 11, 630842	2
302	Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S. <b>2021</b> , 26, e905-e906	3
301	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <b>2021</b> , 15, 84-97	1
300	A qualitative framework of non-selection factors for cytoreductive nephrectomy. <b>2021</b> , 39, 3359-3365	2
299	[Renal cell carcinoma in the department of Hôpital: Results over a 30 year period]. <b>2021</b> , 31, 175-182	1
298	Consensus statements on the management of metastatic renal cell carcinoma from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology 2019. <b>2021</b> , 17 Suppl 3, 27-38	0
297	Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma. <b>2021</b> , 21, 693-703	1
296	Comprehensive review of chromophobe renal cell carcinoma. <b>2021</b> , 160, 103287	7
295	Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice. <b>2021</b> , 11, 657639	7
294	CircEHD2, CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma. <b>2021</b> , 13,	7
293	Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature. <b>2021</b> , 160, 103293	3
292	Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients. <b>2021</b> , 7, 598-607	1
291	Delayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic. <b>2021</b> , 39, 4295-4303	4
290	Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group. <b>2021</b> , 7, 671-685	0

289	Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach. <b>2021</b> , 32, 675-680	0
288	Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma. <b>2021</b> , 11, 634830	2
287	Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature. <b>2021</b> , 28, 1921-1926	1
286	Clear cell renal cancer metastasis in the contralateral ureter: a case report. <b>2021</b> , 15, 309	
285	Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. <b>2021</b> ,	1
284	Surgery for renal cell carcinoma extending to the right atrium in Japanese institutions: Focusing on cardiopulmonary bypass with or without deep hypothermic circulatory arrest. <b>2021</b> , 28, 1001-1007	
283	In the Age of Immunotherapy, How Can We Translate the CARMENA Results into Practice?. <b>2021</b> , 4, 515-516	
282	Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). <b>2021</b> , 11, 682449	3
281	Nephrectomy improves the survival of metastatic renal cell cancer patients with moderate to good performance status-results from a Finnish nation-wide population-based study from 2005 to 2010. <b>2021</b> , 19, 190	1
280	Renal cancer: Key studies for FRCS (Urol). 205141582110264	
279	Metastatic Renal Cell Carcinoma Presenting as Gastrointestinal Bleeding. <b>2021</b> , 15, 478-481	2
278	Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review. <b>2021</b> , 17, 2671-2681	2
277	Debulking surgery for malignant tumors: the current status, evidence and future perspectives. <b>2021</b> , 51, 1349-1362	1
276	Tumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multi-institutional study. <b>2021</b> , 28, 1075-1076	2
275	Postoperative and Survival Outcomes After Cytoreductive Surgery in the Treatment of Metastatic Upper Tract Urothelial Carcinoma. <b>2021</b> , 153, 244-249	
274	Evolution of risk stratification systems is critical for improving patient selection for cytoreductive nephrectomy. <b>2021</b> , 127, 3920-3923	
273	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. <b>2021</b> , 127, 3946-3956	2
272	Metastatic Lesion of the Tibia from Renal Cell Carcinoma. <b>2021</b> , 2021, 2428820	

271	Clearing up Clear Cell: Clarifying the Immuno-Oncology Treatment Landscape for Metastatic Clear Cell RCC. <b>2021</b> , 13,	2
270	Do Metastatic Kidney Cancer Patients Benefit From Cytoreductive Nephrectomy? A Real-World Retrospective Study From the SEER Database. <b>2021</b> , 8, 716455	0
269	Transition to Targeted Therapies Improved the Prognosis and Increased the Utilization of Medical Treatments among Patients with Synchronous Metastatic Renal Cell Cancer. <b>2021</b> , 2021, 5237695	
268	Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC). <b>2021</b> , 13,	2
267	Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial. <b>2021</b> , 80, 325-329	5
266	Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights. <b>2021</b> ,	3
265	Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16). <b>2021</b> , 99, 747-755	2
264	Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news. <b>2021</b> , 99, 102239	5
263	Clinical Review on the Management of Metastatic Renal Cell Carcinoma. <b>2021</b> , OP2100419	8
262	Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib. <b>2021</b> ,	1
261	Loss of Von Hippel-Lindau () Tumor Suppressor Gene Function: -HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC). <b>2021</b> , 22,	7
260	A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer. <b>2021</b> , 39, 548-560	2
259	Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. <b>2021</b> , 39, 837.e9-837.e17	1
258	External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study. <b>2021</b> , 39, 836.e11-836.e17	
257	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. <b>2021</b> , 51, 1751-1756	1
256	Update on the Role of Imaging in Clinical Staging and Restaging of Renal Cell Carcinoma Based on the AJCC 8th Edition, From the Special Series on Cancer Staging. <b>2021</b> , 217, 541-555	1
255	Surgical Insights for the Management of Variant Histology in Renal Cell Carcinoma. <b>2021</b> , 47, 935-942	1
254	Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions. <b>2021</b> , 39, 664-677	3

253	Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?. <b>2021</b> , 80, 417-424	11
252	Tumour Seeding After a Thoracic Biopsy for Renal Cell Carcinoma: A Case Report and a Review of the Literature. <b>2021</b> , 15, 11795549211022261	
251	Spontaneous regression of multiple pulmonary metastases accompanied by normalization of serum immune markers following cytoreductive nephrectomy in a patient with clear-cell renal cell carcinoma. <b>2021</b> , 4, 95-99	1
250	Systemic Therapies for the Treatment of Renal Cell Carcinoma. <b>2020</b> , 401-409	1
249	Surgery in renal cell carcinoma—when, whom and how?. <b>2019</b> , 12, 347-351	0
248	Re: Pathologic Response and Surgical Outcomes in Patients Undergoing Nephrectomy Following Receipt of Immune Checkpoint Inhibitors for Renal Cell Carcinoma. <b>2020</b> , 78, 288	1
247	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <b>2020</b> , 38, 1081	48
246	C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study. <b>2019</b> , 25, 8984-8994	1
245	Predictors of Cytoreductive Nephrectomy for Metastatic Kidney Cancer in SEER and Metropolitan Detroit Databases. <b>2019</b> , 6, 13-25	3
244	A Case of Metastatic Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome-Associated Renal Cell Carcinoma Treated with a Sequence of Axitinib and Nivolumab Following Cytoreductive Nephrectomy. <b>2020</b> , 7, 6-10	2
243	Consideration in the management of renal cell carcinoma during the COVID-19 Pandemic. <b>2020</b> , 46, 69-78	7
242	Renal cell carcinoma: What's new in 2018. <b>2019</b> , 14, 48-52	3
241	Renal cell carcinoma: what's new in 2019. <b>2020</b> , 15, 120-125	2
240	Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology. <b>2019</b> , 10, 942-952	9
239	Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. <b>2020</b> , 11, 4582-4592	2
238	Strengthening the foundation of kidney cancer treatment and research: revising the AJCC staging system. <b>2019</b> , 7, S33	6
237	Current landscape of cytoreductive nephrectomy: who, when, and why?. <b>2019</b> , 7, S77	1
236	Lack of evidence regarding bone metastases of genitourinary cancers: interventions by surgery, radiotherapy, and bone-targeted systemic therapy. <b>2019</b> , 7, S92	1

235	Systemic therapy for metastatic renal cell carcinoma-is timing everything?. <b>2019</b> , 7, S185	2
234	Minimally invasive radical nephrectomy: a contemporary review. <b>2020</b> , 9, 3112-3122	3
233	Cytoreductive nephrectomy for metastatic renal cell carcinoma, the ultimate urologic 'Choosing Wisely' campaign: a narrative review. <b>2020</b> , 9, 7337-7349	8
232	The role of sunitinib in the therapy of metastatic renal cell carcinoma. <b>2020</b> , 136-145	2
231	Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. <b>2020</b> , 14, 1036	1
230	Combination drug regimens for metastatic clear cell renal cell carcinoma. <b>2020</b> , 11, 541-562	10
229	Refractory Renal Cell Cancer with Gastro-renal Fistula: A Rare Complication. <b>2020</b> , 12, e6580	0
228	Response to Soran et al. <b>2021</b> ,	
227	Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: Is There Still a Debate?. <b>2021</b> , 22, 54	0
226	Resection of Asymptomatic Primary Tumor with Synchronous Unresectable Colorectal Metastasis-Is It Reasonable?. <b>2021</b> , 12, 655-657	
225	Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma. <b>2022</b> , 40, 13.e19-13.e27	1
224	Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative. <b>2021</b> , 39, 836.e19-836.e27	2
223	Tumour burden and efficacy of immune-checkpoint inhibitors. <b>2021</b> ,	17
222	Metastasectomy in kidney cancer: current indications and treatment approaches. <b>2021</b> , 15, 266-275	0
221	Renal Cell Carcinoma. <b>2017</b> ,	
220	Health-care expenses - A need to be cautious. <b>2018</b> , 34, 237-238	
219	Quelle stratégie thérapeutique pour les stades métastatiques ?. <b>2018</b> , 20, 211-219	
218	Did you feel the earth shake? An Online Cancer Community Interprets Results of the CARMENA Trial (Preprint).	

- 217 Kidney Cancer: From Basics to Immunotherapy. **2019**, 625-657
- 216 Oncourologist's opinion on the results of the CARMENA study. **2019**, 8, 26-29
- 215 Potential biological and clinical benefit of prostate-directed interventions in patients with metastatic prostate cancer. **2019**, 7, S46
- 214 Editorial on "Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era". **2019**, 7, S36
- 213 Re: Comparison of immediate deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial.. **2019**, 8, S208-S210
- 212 Role of cytoreductive nephrectomy in metastatic renal cell carcinoma patients with tumor thrombus: does it change with development of systemic therapy?. **2019**, 7, S145
- 211 Stereotactic body radiation therapy for oligometastatic renal cell carcinoma: improving outcomes in an otherwise radioresistant malignancy. **2019**, 7, S98
- 210 34th Annual Congress of the European Association of Urology in 2019: Review of oncological urology topics. **2019**, 15, 143-147
- 209 Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-trends and effect on overall survival. **2019**, 7, S196
- 208 Nephrectomy in metastatic renal cell carcinoma with venous thrombus: more thrombus equals less benefit?. **2019**, 7, S186
- 207 Defining an Individualized Treatment Strategy for Metastatic Renal Cancer. **2020**, 437-452
- 206 Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. **2020**, 411-435
- 205 Outcomes: Prognostic Factors, Models, and Algorithms. **2020**, 345-359
- 204 Surgical Consideration in Renal Tumors. **2020**, 3-20
- 203 Cytoreductive nephrectomy following treatment with anti-vascular endothelial growth factor-targeted agents: is it surgically safe?. **2019**, 7, S347
- 202 Prognostic Significance of Systemic Inflammatory Response in Patients with Synchronous and Metachronous Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors. **2019**, 17, 150-159
- 201 Encyclopedia of Gerontology and Population Aging. **2020**, 1-11
- 200 Is there still a role for cytoreductive nephrectomy in metastatic renal cancer in the era of targeted therapy and immunotherapy?. **2020**, 4, 12

199	Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib. <b>2020</b> , 11, 1922-1928	0
198	Latest progress in molecular biology and treatment in genitourinary tumours. <b>2020</b> , 22, 2175-2195	1
197	A Population Study to Identify Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Sarcomatoid Renal Cell Carcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database. <b>2020</b> , 26, e921297	2
196	Medical Management of Renal Cell Cancer.	
195	Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial. <b>2021</b> ,	1
194	Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers. <b>2021</b> ,	0
193	Clinicopathological Study of the Immunohistological Expression of mTOR and Phosphorylated mTOR in Renal Cell Carcinoma. <b>2020</b> , 66, 206-212	
192	Long-Term Outcomes in Clear-Cell Renal Cell Carcinoma Patients Treated with Complete Metastasectomy. <b>2020</b> , 4, 177-183	1
191	Emerging Therapies for Advanced Clear Cell Renal Cell Carcinoma. <b>2020</b> , 7, 17-26	1
190	The role of open radical nephrectomy in contemporary management of renal cell carcinoma. <b>2020</b> , 9, 3123-3139	0
189	Cáncer renal avanzado, perfiles para los nuevos tratamientos. <b>2022</b> , 5, 100277	
188	Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma.. <b>2021</b> , 7,	1
187	Operative Therapie des Nierenzellkarzinoms. <b>2020</b> , 137-155	
186	Epistaxis presenting as sentinel feature of metastatic renal cell carcinoma: A case report and review of literature. <b>2020</b> , 9, 3766-3769	0
185	Cancer Surgery in Challenging Time of COVID-19 Pandemic [A Pragmatic Approach]. <b>2020</b> , 41, 144-148	
184	Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation. <b>2021</b> , 11, 762547	1
183	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <b>2021</b> , 81, 266-266	4
182	The role of cytoreductive nephrectomy in renal cell carcinoma patients with liver metastasis. <b>2021</b> , 21, 229-234	2

- 181 Multidisciplinary Management of Advanced Kidney Cancer. **2020**, 18, 977-981
- 180 [Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma]. **2020**, 51, 572-581 3
- 179 Long-term follow-up results of patients with sarcomatoid RCC: A retrospective evaluation of a single center experience. **2020**, 4, 803-807
- 178 [French ccAFU guidelines - update 2020-2022: management of kidney cancer]. **2020**, 30, S2-S51 3
- 177 An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study. **2021**, 51, 484-491 1
- 176 A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial. **2020**, 11, 4457-4462 1
- 175 The role of radiotherapy in metastatic prostate cancer. **2019**, 7, 92-97 2
- 174 Bladder Cancer Academy 2019 Selected Summaries. **2019**, 21, 23-28 2
- 173 Management of Oligometastatic Prostate Cancer. **2020**, 9, 6-10 2
- 172 Radical nephrectomy with resection of vena cava thrombus using extracorporeal circulation and deep hypothermic circulatory arrest. **2021**, 15, E199-E204
- 171 The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma. **2021**, 37, 13-19 1
- 170 Nierenzellkarzinom. **2022**, 304-307
- 169 "Immune-Cell Pawns" Plot Promotion and Corner Kidney Cancer: CheckMate 214. **2021**,
- 168 Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies.. **2021**, 28, 4894-4928
- 167 Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A Review. **2021**, 2
- 166 Novel cut-off values of time from diagnosis to systematic therapy predict the overall survival and the efficacy of targeted therapy in renal cell carcinoma: A long-term, follow-up, retrospective study. **2021**, 0
- 165 Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data. **2021**, 8, 763271 1
- 164 Second Primary Renal Cell Carcinoma With Nonrenal Malignancies: An Analysis of 118 Cases and a Review of Literature.. **2021**, 11, 780130 0



163	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. <b>2021</b> , 6, 100304	0
162	[Interdisciplinary recommendations for the treatment of advanced renal cell carcinoma]. <b>2021</b> ,	
161	The Search for the Optimal Immunotherapy Sequencing in the Perioperative Setting of RCC. <b>2022</b> , 207-220	
160	Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma.. <b>2022</b> ,	0
159	Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment.. <b>2022</b> , 35, 54-58	2
158	Cytoreductive Nephrectomy: Still Necessary in 2021.. <b>2022</b> , 36, 49-50	3
157	Cytoreductive Nephrectomy in 2021: Obsolete but Necessary.. <b>2022</b> , 36, 41-43	1
156	Radical nephrectomy with resection of vena cava thrombus using extracorporeal circulation and deep hypothermic circulatory arrest. <b>2020</b> , 15, E199-E204	
155	Tumors: Urologic Cancer. <b>2021</b> , 5291-5301	
154	Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <b>2021</b> ,	2
153	Collecting duct carcinoma of the kidney: Analysis of 74 cases from multiple centers.. <b>2022</b> ,	1
152	piRNAs and PIWI Proteins as Diagnostic and Prognostic Markers of Genitourinary Cancers.. <b>2022</b> , 12,	0
151	Surgical outcomes for older patients with renal cell carcinoma and inferior vena cava thrombus.. <b>2022</b> , 40, 110.e11-110.e11	0
150	Surgical Treatment for Metastatic Kidney Cancer. <b>2022</b> , 243-262	
149	The Value of Metastasectomy in Renal Cell Carcinoma in 2021. 1	
148	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.. <b>2022</b> , 20, 71-90	20
147	Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study.. <b>2022</b> , 27, 563	1
146	Is a single portal venous phase in contrast-enhanced CT sufficient to detect metastases or recurrence in clear cell renal cell carcinoma? - a single-center retrospective study.. <b>2022</b> , 22, 9	

145 Supportive and Palliative Care for Genitourinary Malignancies. **2022**, 15-60

144 Cytoreductive Nephrectomy in the Era of Targeted Therapy and Immunotherapy. **2022**, 179-185

143 Selection of Optimal Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Clear Cell Renal Cell Carcinoma: A Predictive Model Based on SEER Database.. **2022**, 12, 814512 1

142 Recent Advances in First-Line Management of Metastatic Renal Cell Carcinoma.

141 Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma.. **2022**, 0

140 Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus.. **2022**, 0

139 Uveal melanoma metastatic at initial diagnosis: a case series.. **2022**, 32, 0

138 Nierenzellkarzinom. **2022**, 130-134

137 Letter to the Editor From de Ponthaud et al: "Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival".. **2022**, 0

136 Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.. **2022**, 23, 609 0

135 Surgical and focal treatment for metastatic renal cell carcinoma: A literature review.. **2022**, 0

134 Targeting circDGKD Intercepts TKI's Effects on Up-Regulation of Estrogen Receptor and Vasculogenic Mimicry in Renal Cell Carcinoma.. **2022**, 14, 0

133 Benefit of Metastasectomy in Renal Cell Carcinoma: A Propensity Score Analysis.. **2022**, 0

132 "PROBE"ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer.. **2022**, 6, 3-9 0

131 Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation.. **2022**, 5, 168-171 1

130 Tumor-Educated Platelets as a Promising Biomarker for Blood-Based Detection of Renal Cell Carcinoma.. **2022**, 12, 844520 1

129 Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.. **2022**, 0

128 Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents.. **2022**, 1 0

- 127 A Simple-To-Use Nomogram for Predicting Early Death in Metastatic Renal Cell Carcinoma: A Population-Based Study.. **2022**, 9, 871577 0
- 126 Clinicopathological and Molecular Features of Secondary Cancer (Metastasis) to the Thyroid and Advances in Management.. **2022**, 23, 1
- 125 Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG).. **2022**, 7, 100402 0
- 124 Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options.. **2022**, 1-9 0
- 123 Trans-arterial embolization of renal cell carcinoma: a systematic review and meta-analysis.. **2022**, 1 0
- 122 The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis.. **2022**, 108, 108720 1
- 121 Cŕcer Renal Hereditario Bilateral en Von Hippel Lindau.. **2020**, 8, 28-30
- 120 Metastatic Tumours: Cytoreductive Nephrectomy. **2022**, 211-222
- 119 Triceps mass - A rare presentation of renal cell carcinoma.. **2022**, 43, 102079
- 118 Identification of BAP1 mutation as a common mutation correlated with tumor mutation burden and immune infiltration in kidney renal clear cell carcinoma. **2022**, 15, 470-478 0
- 117 Shifting role of cytoreductive nephrectomy according to type of systemic therapy: A nationwide cohort study.. **2022**,
- 116 Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma. 1 1
- 115 Image\_1.tif. **2020**,
- 114 Image\_2.tif. **2020**,
- 113 Image\_1.JPEG. **2019**,
- 112 Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era.. **2022**, 1 0
- 111 WHO SHOULD RECEIVE RADIOTHERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER?. **2019**, 58, 36-41
- 110 Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study.. **2022**, 1 1

- 109 Complete response of metastatic renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus ipilimumab. 0
- 108 Stauffer syndrome: a comprehensive review of the disease and diagnostic plan proposal. **2022**, 34, 0
- 107 Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma.. **2022**, 0
- 106 Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study.. **2022**, 14, 0
- 105 Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. **2022**, 40, 38-45 0
- 104 Kidney Cancer. **2022**, 233-245
- 103 Long Non-Coding RNAs as Novel Biomarkers in the Clinical Management of Papillary Renal Cell Carcinoma Patients: A Promise or a Pledge?. **2022**, 11, 1658 0
- 102 Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.. **2022**, 5, e2212347 2
- 101 Isolated soft tissue mass of the finger as the first presentation of oligometastatic renal cell carcinoma.. **2022**, 15, 1
- 100 Non-prostate Genitourinary Cancers. **2022**, 411-423
- 99 Kidney Cancer. **2022**, 1019-1038
- 98 New Paradigms for Cytoreductive Nephrectomy. **2022**, 14, 2660 0
- 97 The Role of Cytoreductive Nephrectomy and Targeted Therapy on Outcomes of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: A Population-Based Analysis. **2022**,
- 96 First-line therapy for metastatic renal cell carcinoma. 205141582210929
- 95 Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018. **2022**, 152,
- 94 Editorial Comment from Dr Nagata to Nomogram for predicting survival of renal cell carcinoma with tumor thrombus based on perioperative clinicopathological factors from a Chinese high-volume center.
- 93 Surgical management in metastatic renal cell carcinoma. **2022**, 109, 2S59-2S65
- 92 Efficacy of the 1<sup>st</sup> generation tyrosine kinase inhibitor sunitinib in the treatment of metastatic renal cell carcinoma in alternative dosing regimens. **2022**, 85-92

91 Special issue "The advance of solid tumor research in China" Presurgical therapy in the management of local retroperitoneal recurrence of renal cell carcinoma after radical nephrectomy.

90 An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. 0

89 What we have learnt from CARMENA and SURTIME and what should be done differently in future trials on cytoreductive nephrectomy. **2022**, 1-9

88 Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. 7

87 Tumor shrinkage patterns of nivolumab monotherapy in metastatic renal cell carcinoma.

86 Construction and validation of a novel prognostic nomogram for patients with metastatic renal cell carcinoma: a SEER-based study. **2022**, 50, 030006052211053

85 The Role of Cytoreductive Nephrectomy in the Treatment of Metastatic Renal Cell Carcinoma. **2022**, 12, 6168-6172

84 Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib. **2022**, 0

83 Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients With Renal Cell Carcinoma and Venous Tumor Thrombus: A Population-Based Study. 9,

82 Combination therapy regimens in the treatment of metastatic renal cell carcinoma: A review. **2022**, 24, 191-198

81 Local Treatment of the Primary Tumor for Patients with Metastatic Cancer (PRIME-TX): A Meta-analysis.. **2022**, 0

80 Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. 0

79 Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma. **2022**, 2

78 Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma. **2022**, 40, 385.e1-385.e8

77 Renal Tumors. **2023**, 285-308

76 The role of hepatic and pancreatic metastatectomy in the management of metastatic renal cell carcinoma: A systematic review. *Surgical Oncology*, **2022**, 101819 2.5

75 Advantages of organ-sparing treatment approaches in metastatic kidney cancer.

74 New Therapeutic Interventions for Kidney Carcinoma: Looking to the Future. **2022**, 14, 3616 2

- 73 Is Cytoreductive Nephrectomy Still Beneficial for Patients With Metastatic Renal Cell Carcinoma in the Contemporary Immunotherapy Era?. **2022**, 20, 139-150
- 72 A Swinging Pendulum: Bringing Back Cytoreductive Nephrectomy in the Era of Immune Checkpoint Inhibition. **2022**,
- 71 The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature. **2022**, 29, 5475-5488 2
- 70 2021 Consensus Statements on the Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma From the Korean Renal Cancer Study Group (KRCS). **2022**, 20, 151-162
- 69 Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study).
- 68 Effect of Inferior Vena Cava Tumor Thrombus on Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Cytoreductive Nephrectomy. **2022**, 44, 94-101 0
- 67 Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Pro. **2022**, 44, 92-93 0
- 66 Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Con. **2022**, 44, 81-83 0
- 65 Tratamiento contemporáneo del cáncer renal avanzado: de la vigilancia a la inmunoterapia. **2022**, 20, 342-346 0
- 64 Interpreting the results of noninferiority trials: a review. 0
- 63 Wertigkeit der Nephrektomie. **2022**, 26, 32-34 0
- 62 Discovery of a novel monoclonal PD-L1 antibody H1A that promotes T-cell mediated tumor killing activity in renal cell carcinoma. 1
- 61 The role of surgery for loco-regional and advanced urological cancers. **2022**, 32, 634-642 0
- 60 The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review. **2022**, 0
- 59 Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma. **2022**, 14, 4607 0
- 58 SPOP could play a potential inhibitory role in human renal cell carcinoma. 0
- 57 The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study. **2022**, 20, 0
- 56 The Emerging Role of Radiation Therapy in Renal Cell Carcinoma. **2022**, 14, 4693 2

55	Impact of atrial fibrillation on the risk of major adverse cardiac events following coronary revascularisation. <b>2022</b> , 9, e002012	0
54	Tratamiento del cáncer de riñón metastásico. <b>2022</b> , 54, 1-13	0
53	Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis. <b>2022</b> ,	0
52	Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years' experience at a regional cancer Centre.	0
51	Letter to the editor on Trans-arterial embolization of renal cell carcinoma: a systematic review and meta-analysis	0
50	The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis. <b>2022</b> , 14, 5258	0
49	Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. <b>2022</b> ,	3
48	A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy. <b>2022</b> ,	0
47	Renal Cell Carcinoma. 1-10	0
46	Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy. Volume 14, 3071-3081	0
45	Effects of Different Organ Metastases on the Prognosis of Stage IV Urothelial Carcinoma of the Bladder. <b>2022</b> , 2022, 1-12	0
44	Hot topics in renal cancer pathology: implications for clinical management.	0
43	Should We Always Perform Preoperative Chest Computed Tomography in Patients with cT1a Renal Cell Carcinoma?. <b>2022</b> , 14, 5558	0
42	Primary Cytoreductive Nephrectomy: Standing the Test of Time?. <b>2022</b> ,	0
41	French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer. <b>2022</b> , 32, 1195-1274	0
40	Activity of Immunotherapy Regimens on Primary Renal Tumours: A Systematic Review. <b>2022</b> , 1-16	1
39	Review of Robotic-Assisted Radical Nephrectomy with Inferior Vena Cava Thrombectomy in Renal Cell Carcinoma.	0
38	Cytoreductive Surgery in Patients with Urothelial Bladder Cancer. <b>2022</b> ,	0

- 37 Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah's witness: A case report. 12, 0
- 36 KCMF1 regulates autophagy and ion channels function in renal cell carcinoma: a future therapeutic target. 0
- 35 Speckle-type POZ protein could play a potential inhibitory role in human renal cell carcinoma. 2022, 22, 0
- 34 Web-Based Nomograms for Overall Survival and Cancer-Specific Survival of Bladder Cancer Patients with Bone Metastasis: A Retrospective Cohort Study from SEER Database. 2023, 12, 726 0
- 33 The Role of Immunotherapy in Renal Cell Carcinoma. 2023, 1-31 0
- 32 Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy. 2023, 1
- 31 Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial. 0
- 30 Cytoreductive nephrectomy for synchronous metastatic renal cell carcinoma. Is there enough evidence?. 2022, 94, 476-485 0
- 29 A comprehensive analysis of the FOX family for predicting kidney renal clear cell carcinoma prognosis and the oncogenic role of FOXG1. 2022, 14, 10107-10124 0
- 28 Wann organerhaltende Tumorsektion, wann Tumornephrektomie beim Nierenzellkarzinom?. 0
- 27 Clear Cell Renal Cell Carcinoma: From Biology to Treatment. 2023, 15, 665 2
- 26 Renal cancer. 175573802211487 0
- 25 The role of cytoreductive nephrectomy in the immuno-oncological therapy era. Publish Ahead of Print, 0
- 24 Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy. 0
- 23 Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?. 1-14 0
- 22 Integrated analysis of the relation to tumor immune microenvironment and predicted value of Stonin1 gene for immune checkpoint blockage and targeted treatment in kidney renal clear cell carcinoma. 2023, 23, 0
- 21 The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size  $\geq$  4 cm. 2023, 0
- 20 Integrating Surgery in the Multidisciplinary Care of Advanced Renal Cell Carcinoma. 2023, 50, 311-323 0



- 19 Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma. **2023**, 35, 206-217 ○
- 18 Re: Ithaar H. Derweesh, Rana R. McKay, Aditya Bagrodia. Primary Cytoreductive Nephrectomy: Standing the Test of Time? *Eur Urol.* 2023;83:152B. **2023**, 83, e135 ○
- 17 Surgical Management of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus. **2023**, 50, 261-284 ○
- 16 Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma. **2022**, 237-245 ○
- 15 Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. **2023**, 1
- 14 Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma. **2023**, 9, 275-277 ○
- 13 Approaches to Oligometastatic Renal Cell Carcinoma. **2023**, 25, 251-256 ○
- 12 Stereotactic body radiation therapy to the kidney for metastatic renal cell carcinoma: A narrative review of an emerging concept. **2023**, 35, 100692 ○
- 11 Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. **2023**, ○
- 10 The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma. ○
- 9 The impact of cytoreductive nephrectomy on survival outcomes in patients with metastatic renal cell carcinoma receiving immunotherapy: An evidence-based analysis of comparative outcomes. 14, ○
- 8 Surgical Approach in Metastatic Renal Cell Carcinoma: A Literature Review. **2023**, 15, 1804 ○
- 7 A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy. ○
- 6 Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab. **2023**, 12, 2417 ○
- 5 Treatment strategies for clear cell renal cell carcinoma: Past, present and future. 13, ○
- 4 Tumores renales. **2023**, ○
- 3 Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. **2023**, ○
- 2 What is the role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma?. 1-5 ○

- 1 Résultats de la prise en charge des cancers du rein avec extension dans la veine cave inférieure :  
Étude observationnelle rétrospective monocentrique. **2023**, ○